Needham Reiterates Buy on Viridian Therapeutics, Maintains $32 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.6%

Neg 0% Neu 87.6% Pos 0%

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $32 price target.